Akebia's Cash Surges Amidst Auryxia Generic Threat

TL;DR

**AKBA's cash pile is growing, but Auryxia's generic hit and internal control issues make it a risky bet.**

AI Summary

Akebia Therapeutics, Inc. reported a significant increase in cash and cash equivalents to $166,444 thousand as of September 30, 2025, up from $51,870 thousand at December 31, 2024. Total assets grew to $364,152 thousand from $220,670 thousand in the same period. Accounts receivable, net, more than doubled to $66,223 thousand from $34,368 thousand, indicating stronger sales or slower collections. Current liabilities also saw a substantial rise, with accrued expenses and other current liabilities increasing to $106,420 thousand from $63,460 thousand. The company's business remains heavily dependent on the commercial success of Auryxia and Vafseo, with the loss of exclusivity for Auryxia in March 2025 posing a significant risk due to generic competition. A material weakness in internal control over financial reporting related to inventory accounting as of December 31, 2024, continues to be a concern, potentially impacting financial reporting accuracy. The company anticipates continued losses and may require substantial additional financing to fund operations, which could dilute existing stockholders.

Why It Matters

Akebia's substantial increase in cash and accounts receivable suggests a period of strong operational activity, potentially driven by Vafseo's commercialization. However, the looming threat of generic competition for Auryxia, which lost exclusivity in March 2025, could severely impact future revenue, directly affecting investor returns and the company's ability to fund R&D. The identified material weakness in inventory accounting raises red flags for investors regarding financial transparency and internal controls, potentially eroding trust. For employees, the company's need for additional financing and the competitive landscape could signal future workforce adjustments or strategic shifts. In the broader market, Akebia's performance in the kidney disease therapeutic area, particularly with Vafseo, influences competitive dynamics with other pharmaceutical companies.

Risk Assessment

Risk Level: high — Akebia faces a high risk level due to several factors. The company explicitly states, "We have incurred significant losses since our inception, and anticipate that we will continue to incur losses and cannot guarantee when, if ever, we will become and remain profitable." Furthermore, the loss of exclusivity for Auryxia in March 2025 and the anticipated entry of generic versions pose a direct threat to a substantial portion of their revenue, as their business is "substantially dependent on the commercial success of Auryxia and Vafseo." The identified "material weakness in our internal control over financial reporting as of December 31, 2024 relating to our accounting for inventory and inventory related transactions" adds significant operational and financial reporting risk.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Akebia's ability to mitigate the impact of Auryxia's generic competition and successfully commercialize Vafseo. Monitor the remediation efforts for the material weakness in internal controls and any updates on future financing needs, as these will be critical for the company's long-term viability. Consider the potential for significant stock price volatility.

Financial Highlights

debt To Equity

N/A

revenue

$178,574

operating Margin

N/A

total Assets

$364,152

total Debt

$47,641

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

$166,444

revenue Growth

+57.1%

Revenue Breakdown

Key Numbers

• $166.4M — Cash and cash equivalents (Increased from $51.9M at Dec 31, 2024, indicating improved liquidity.)
• $364.2M — Total assets (Increased from $220.7M at Dec 31, 2024, reflecting overall growth.)
• $66.2M — Accounts receivable, net (Increased from $34.4M at Dec 31, 2024, suggesting higher sales or slower collections.)
• $106.4M — Accrued expenses and other current liabilities (Increased from $63.5M at Dec 31, 2024, indicating higher short-term obligations.)
• 265,365,993 — Shares outstanding (As of November 4, 2025, relevant for per-share metrics.)
• 2025-09-30 — Quarter end date (Financial reporting period for the 10-Q.)
• 2024-12-31 — Prior fiscal year end (Comparative financial reporting period.)

Key Players & Entities

• Akebia Therapeutics, Inc. (company) — Registrant of the 10-Q filing
• Auryxia (company) — Key commercial product facing generic competition
• Vafseo (company) — Key commercial product for which label expansion is sought
• Keryx Biopharmaceuticals, Inc. (company) — Acquired subsidiary in December 2018
• HealthCare Royalty Partners IV, L.P. (company) — Party to a Royalty Interest Acquisition Agreement
• BlackRock (company) — Lender in the BlackRock Credit Agreement
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Capital Market (regulator) — Exchange where Common Stock is registered
• November 4, 2025 (date) — Date for outstanding common stock count
• March 2025 (date) — Date of Auryxia's loss of exclusivity

FAQ

Risk Factors

• Auryxia Exclusivity Loss [high — market]: The loss of exclusivity for Auryxia in March 2025 due to generic competition poses a significant risk to future revenue streams. This could lead to a substantial decline in product revenue if generic alternatives capture a significant market share.
• Internal Control Weakness [medium — operational]: A material weakness in internal control over financial reporting related to inventory accounting as of December 31, 2024, persists. This raises concerns about the accuracy and reliability of financial reporting, particularly concerning inventory valuation and cost of goods sold.
• Need for Additional Financing [high — financial]: The company anticipates continued losses and may require substantial additional financing to fund operations. This could lead to dilution of existing stockholders' equity if new shares are issued at unfavorable prices.
• Regulatory Compliance [medium — regulatory]: As a pharmaceutical company, Akebia is subject to extensive regulatory oversight from bodies like the FDA. Changes in regulations or failure to comply could impact product approvals, marketing, and overall business operations.
• Competition [medium — market]: The company faces competition from other pharmaceutical companies in the nephrology space. The success of its products depends on differentiation and market acceptance against existing and emerging therapies.

Industry Context

The pharmaceutical industry, particularly in the nephrology sector, is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Companies rely on product innovation and effective commercialization to achieve profitability. The increasing prevalence of chronic kidney disease globally presents a growing market, but also attracts significant competition.

Regulatory Implications

Akebia operates in a highly regulated environment. Any changes in FDA regulations, pricing controls, or post-market surveillance requirements could materially impact its business. The company must maintain robust compliance programs to navigate these complexities and ensure continued market access for its products.

What Investors Should Do

1. Monitor Auryxia generic entry impact
2. Evaluate financing needs and dilution risk
3. Assess internal control remediation progress
4. Analyze cash burn rate and runway

Key Dates

• 2025-03-01: Loss of Exclusivity for Auryxia — Marks the beginning of generic competition for a key product, posing a significant revenue risk.
• 2025-09-30: Quarter End Date — Reporting date for the unaudited condensed consolidated financial statements.
• 2024-12-31: Prior Fiscal Year End — Comparative period for balance sheet items and context for internal control weaknesses.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net gains. It represents the cumulative loss that has not been offset by profits. (Indicates the company has historically operated at a loss, impacting its equity position.)

Operating right-of-use assets

Assets recognized under lease accounting standards representing the right to use an underlying asset for the lease term. (Reflects the company's obligations related to leases for property and equipment.)

Liability related to settlement royalties

An obligation to pay royalties as part of a settlement agreement, likely related to past legal or licensing disputes. (Represents a significant long-term financial commitment impacting cash flows.)

Material weakness

A deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (Highlights a significant concern regarding the reliability of the company's financial reporting.)

Year-Over-Year Comparison

Compared to the prior fiscal year end (December 31, 2024), Akebia Therapeutics has significantly improved its liquidity, with cash and cash equivalents increasing from $51.9 million to $166.4 million. Total assets have also grown substantially to $364.2 million from $220.7 million. However, current liabilities have also risen, with accrued expenses and other current liabilities increasing from $63.5 million to $106.4 million, indicating growing short-term obligations. The company's revenue for the nine months ended September 30, 2025, shows a strong increase of 57.1% year-over-year, reaching $178.6 million from $113.7 million in the prior year period, driven by product sales.

Key Financial Figures

• $0.00001 — ange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Cap

Filing Documents

• akba-20250930.htm (10-Q) — 2274KB
• exhibit101-akebiaamendment.htm (EX-10.1) — 32KB
• exhibit311-q320251.htm (EX-31.1) — 11KB
• exhibit312-q320251.htm (EX-31.2) — 11KB
• exhibit321-q320251.htm (EX-32.1) — 7KB
• akba-20250930_g1.gif (GRAPHIC) — 4KB
• 0001517022-25-000046.txt ( ) — 10500KB
• akba-20250930.xsd (EX-101.SCH) — 86KB
• akba-20250930_cal.xml (EX-101.CAL) — 84KB
• akba-20250930_def.xml (EX-101.DEF) — 384KB
• akba-20250930_lab.xml (EX-101.LAB) — 861KB
• akba-20250930_pre.xml (EX-101.PRE) — 633KB
• akba-20250930_htm.xml (XML) — 1407KB

Financial Statements (Unaudited)

Item 1 Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheet s 2 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss ) 3 Condensed Consolidated Statements of Stockholders' Equity (Deficit ) 4 Condensed Consolidated Statements of Cash Flows 5 Notes to the Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 30

Quantitative and Qualitative Disclosures A bout Market Risk

Item 3 Quantitative and Qualitative Disclosures A bout Market Risk 45

Controls and Procedures

Item 4 Controls and Procedures 45 Part II 46

Legal Proceedings

Item 1 Legal Proceedings 46

Risk Factors

Item 1A Risk Factors 46

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 108

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 108

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 108

Other Information

Item 5 Other Information 109

Exhibits

Item 6 Exhibits 111

Signatures

Signatures 112 In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to "Akebia," "we," "us," "our," "the Company," "our Company" and similar references refer to Akebia Therapeutics, Inc. and, where appropriate, its consolidated subsidiaries. On December 12, 2018, in connection with the consummation of the merger, or Merger , with Keryx Biopharmaceuticals, Inc., or Keryx , Keryx became a wholly owned subsidiary of the Company. AURYXIA, AKEBIA Therapeutics, Vafseo and their associated logos are trademarks of Akebia and/or its affiliates. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, trademarks, trade names, and service marks referred to in this Quarterly Report on Form 10-Q may appear without the or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other company. Akebia Therapeutics, Inc. | Form 10-Q | Page 1 Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Akebia Therapeutics, Inc. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (dollars in thousands, except per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 166,444 $ 51,870 Inventories 18,643 16,243 Accounts receivable, net 66,223 34,368 Prepaid expenses and other current assets 7,026 11,350 Total current assets 258,336 113,831 Property and equipment, net 1,473 2,200 Operating right-of-use assets 4,837 8,218 Goodwill 59,044 59,044 Other long-term assets 40,462 37,377 Total assets $ 364,152 $ 220,670 Liabilities and stockholders' equity (deficit) Current liabilities: Accounts payable $ 10,087 $ 15,180 Accrued expenses and other current liabilities 106,420 63,460 Current portion of deferred revenue 3,881 — Working Capital Fund liability, current portion 12,991 2,274 Total current liabilities 133,379 80,914 Long-term operating lease liabilities — 3,547 Long-term debt, net 47,641 38,693 Liability related to settlement royalties, net of current portion 52,994 46,697 Liability related to sale of future royalties, net of current portion 50,576 52,066 Working Capital Fund liability, net of current portion 27,726 38,013 Warrant liability 5,242 5,176 Other long-term liabilities 5,002 4,749 Total liabilities 322,560 269,855 Commitments and contingencies (Note 10) Stockholders' equity (deficit): Preferred stock $ 0.00001 par value; 25,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock $ 0.00001 par value; 350,000,000 shares authorized at September 30, 2025 and December 31, 2024; 265,226,038 and 224,848,992 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 2 2 Additional paid-in capital 1,713,045 1,629,167 Accumulated other comprehensive income 6 6 Accumulated deficit ( 1,671,461 ) ( 1,678,360 ) Total

View Full Filing

View this 10-Q filing on SEC EDGAR